目的 探討腎舒顆粒聯(lián)合頭孢哌酮鈉舒巴坦鈉治療慢性腎盂腎炎的臨床療效。方法 選取2015年3月-2016年3月在江油市人民醫(yī)院接受治療的慢性腎盂腎炎患者90例，隨機(jī)分組法分為對照組和治療組，每組各45例。對照組靜脈滴注注射用頭孢哌酮鈉舒巴坦鈉，2 g加入到0.9%氯化鈉注射液100 mL中，2次/d。治療組在對照組基礎(chǔ)上口服腎舒顆粒，2袋/次，3次/d。兩組患者均治療14 d。觀察兩組的臨床療效，比較兩組的臨床癥狀評分和相關(guān)指標(biāo)情況。結(jié)果 治療后，對照組和治療組的總有效率分別為82.22%、95.56%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組尿頻、尿急、尿痛和腰痛評分均明顯下降，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的下降程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組白蛋白（ALB）、β₂-微球蛋白（β₂-MG）、N-乙酰-β-D-氨基葡萄糖苷酶（NAG）和轉(zhuǎn)化生長因子-β₁（TGF-β₁）均明顯下降，而免疫球蛋白A（IgA）和免疫球蛋白G（IgG）均明顯上升，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 腎舒顆粒聯(lián)合頭孢哌酮鈉舒巴坦鈉治療慢性腎盂腎炎具有較好的臨床療效，能改善臨床癥狀，調(diào)節(jié)腎功能，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Shenshu Granules combined with cefoperazone sodium and sulbactam sodium in treatment of chronic pyelonephritis. Methods Patients (90 cases) with chronic pyelonephritis in Jiangyou People's Hospital from March 2013 to March 2015 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were iv administered with Cefoperazone Sodium and Sulbactam Sodium for injection, 2 g added into normal saline 100 mL, twice daily. Patients in the treatment group were po administered with Shenshu Granules on the basis of the control group, 2 bags/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and clinical symptom scores and relevant indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.22% and 95.56%, respectively, and there was difference between two groups (P<0.05). After treatment, the scores of frequent urination, urgency, dysuria, and lumbago in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, ALB, β₂-MG, NAG, and TGF-β₁ in two groups were significantly decreased, but IgA and IgG in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shenshu Granules combined with cefoperazone sodium and sulbactam sodium has clinical curative effect in treatment of chronic pyelonephritis, and can improve clinical symptoms, regulate renal function, which has a certain clinical application value.